Miloš, the first patient with epidermolysis bullosa to receive gene therapy with the drug Vyjuvek at UKC Ljubljana, is showing significantly faster wound healing after three applications with no notable side effects.

Krystal Biotech plans to expand VYJUVEK globally, with a launch in Italy scheduled for the second half of 2026, while maintaining a strong gross margin outlook.